|Awarded On||May 18, 2022|
|Title||Recruitment of Rising Stars|
|Award Mechanism||Recruitment of Rising Stars|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Chistine Lovly|
|Cancer Sites||Lung and Bronchus|
|Summary of Goals and Objectives||
Biomarker testing to inform treatment planning is the standard of care worldwide for patients with non-small cell lung cancer. However, most patients still do not experience long term survival, due to incomplete responses to initial therapy and acquired resistance. The goal of this proposal is to develop novel therapeutic strategies based on an understanding of the genomic, molecular, and cellular changes involved in treatment response/resistance. Our three objectives are integrated under the premise of discovering new paradigms for mechanism-based therapies, each addressing critical gaps where the current framework for precision medicine falls short. (1) While multiple distinct variants can...